Details for Patent: 5,166,174
✉ Email this page to a colleague
| Title: | Prostaglandins E and anti-ulcers containing same |
| Abstract: | The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer. |
| Inventor(s): | Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Kyoto, JP), Kato; Ichie (Kawanishi, JP), Oda; Tomio (Itami, JP) |
| Assignee: | K.K. Ueno Seiyaku Oyo Kenkyujo (Osaka, JP) |
| Filing Date: | May 13, 1991 |
| Application Number: | 07/700,895 |
| Claims: | 1. Prostaglandins E represented by a general formula: in which X represents: ##STR47## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom provided that at least one of R.sub.4 and R.sub.5 is a halogen atom; and R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond. 2. Prostaglandins E as described in claim 1, wherein R.sub.4 and R.sub.5 are halogen atoms. 3. Prostaglandins E as described in claim 1, wherein R.sub.4 and/or R.sub.5 is a fluorine atom. 4. Prostaglandins E as described in claim 1, wherein R.sub.4 or R.sub.5 is a methyl group. 5. Prostaglandins E as described in claim 1 having a methyl group on 19 position thereof. 6. Prostaglandins E as described in claim 1 wherein R.sub.6 is a hexyl group. 7. Prostaglandins E as described in claim 1 wherein R.sub.6 is an isopentyl group. 8. Prostaglandins E as described in claim 1 wherein R.sub.6 is a pentyl-2S-group. 9. Prostaglandins E as described in claim 1 of which carboxyl group on the terminal position of .alpha.-chain is esterified with alkyl group. 10. Prostaglandins E as described in claim 1, which is 13,14-dihydro-15-keto-PGE having one or more fluorine atom on 16-position or alkyl ester thereof. 11. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16R,S-fluoro-PGE.sub.2 or alkyl ester thereof. 12. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.2 or alkyl ester thereof. 13. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16R,S-fluoro-20-methyl-PGE.sub.2 or alkyl ester thereof. 14. Prostaglandin E as described in claim 1, wherein R.sub.6 is a C.sub.5 -C.sub.9 alkyl group. 15. Prostaglandin E as described in claim 2, wherein each of R.sub.4 and R.sub.5 is a halogen atom. 16. Prostaglandin E as described in claim 3, wherein each of R.sub.4 and R.sub.5 is a fluorine atom. 17. Prostaglandin E as described in claim 1, wherein only one of R.sub.4 and R.sub.5 is a halogen atom. 18. Prostaglandin E as described in claim 17, wherein the halogen atom is a fluorine atom. 19. Prostaglandin E as described in claim 1 having a 19-methyl substituent. 20. Prostaglandin E as described in claim 1 having a 20-alkyl substituent. 21. Prostaglandin E as claimed in claim 1, in the form of a mixture of isomers thereof. 22. Prostaglandin E as described in claim 1, wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S,16R,S-difluoro-PGE.sub.2. 23. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E expressed by a general formula: ##STR48## in which X represents: ##STR49## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom provided that at least one of R.sub.4 and R.sub.5 is a halogen atom; and R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond. 24. An antiulcer composition as described in claim 23 wherein R.sub.4 and R.sub.5 are halogen atoms. 25. An antiulcer composition as described in claim 23 wherein R.sub.4 and/or R.sub.5 is a fluorine atom. 26. An antiulcer composition as described in claim 23 wherein R.sub.4 or R.sub.5 is a methyl group. 27. An antiulcer composition as described in claim 23 comprising prostaglandin E of claim 26 having a methyl group on 19-position. 28. An antiulcer composition as described in claim 23 wherein R.sub.6 is a hexyl group. 29. An antiulcer composition as described in claim 23 wherein R.sub.6 is an isopentyl group. 30. An antiulcer composition as described in claim 26 wherein R.sub.6 is a pentyl-2S-group. 31. An antiulcer composition as described in claim 23 wherein the prostaglandines E of which carboxyl group on the terminal position of .alpha.-chain is esterified with alkyl group are contained. 32. An antiulcer composition as described in claim 23 wherein the prostaglandins E are 13,14-dihydro-15-keto-PGEs having one or more fluorine atom on 16-position or alkyl ester thereof. 33. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S-fluoro-PGE.sub.2 or alkyl ester thereof. 34. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.2 or alkyl ester thereof. 35. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S-fluoro-20methyl-PGE.sub.2 or alkyl ester thereof. 36. The anti-ulcer composition of claim 23, wherein the prostaglandin E is in the form of a mixture of isomers thereof. 37. The anti-ulcer composition of claim 23, wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S,16R,S-difluoro-PGE.sub.2. 38. A treatment of ulcer by administering an anti-ulcer treating effective amount of prostaglandin E to a patient, wherein the prostaglandin E is represented by a formula: ##STR50## in which X represents: ##STR51## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom (provided that R.sub.4 and R.sub.5 may be identical with or different from each other); and R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond; except compounds of the formula (I) in which all R.sub.1, R.sub.2, R.sub.4 and R.sub.5 are each hydrogen atoms, R.sub.6 is n-butyl and R.sub.3 is hydroxyl. |
